<p>GSK's drug Blenrep for the treatment of blood cancer failed to gain the support of the U.S. Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC).
The committee's vote was 5-3, indicating that the drug, which is used to treat relapsed or refractory multiple myeloma, is not worth the risk.
This will cast a shadow over the drug's approval prospects</p>

<p>GSK's blood cancer drug Blenrep failed to gain the support of the FDA Oncology Drug Advisory Committee, with a vote result of 5-3, indicating that the drug is considered to be not worth the risk in the treatment of relapsed or refractory multiple myeloma. This result will have a negative impact on the drug's approval prospects</p>

News